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Objectives: To examine the performance of the urinary biomarker
panel tissue inhibitor of metalloproteinase-2 and insulin-like
growth factor-binding protein 7 in patients with sepsis at ICU
www.ccmjournal.org
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admission. To investigate the effect of nonrenal organ dysfunction
on tissue inhibitor of metalloproteinase-2 and insulin-like growth
factor-binding protein 7 in this population.
Method: In this ancillary analysis, we included patients with sepsis
who were enrolled in either of two trials including 39 ICUs across
Europe and North America. The primary endpoint was moderatesevere acute kidney injury (equivalent to Kidney Disease Improving Global Outcome stage 2–3) within 12 hours of enrollment.
We assessed biomarker performance by calculating the area
under the receiver operating characteristic curve, sensitivity, specificity, and negative and positive predictive values at three cutoffs:
0.3, 1.0, and 2.0 (ng/mL)2/1,000. We also calculated nonrenal
Sequential Organ Failure Assessment scores for each patient on
enrollment and compared tissue inhibitor of metalloproteinase-2
and insulin-like growth factor-binding protein 7 results in patients
with and without acute kidney injury and across nonrenal Sequential Organ Failure Assessment scores. Finally, we constructed a
clinical model for acute kidney injury in this population and compared the performance of the model with and without tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding
protein 7.
Results: We included 232 patients in the analysis and 40 (17%)
developed acute kidney injury. We observed significantly higher
urine tissue inhibitor of metalloproteinase-2 and insulin-like
growth factor-binding protein 7 in patients with acute kidney
injury than without acute kidney injury in both patients with low
and high nonrenal Sequential Organ Failure Assessment scores
(p < 0.001). The area under the receiver operating characteristic curve (95% CI) of tissue inhibitor of metalloproteinase-2 and
insulin-like growth factor-binding protein 7 was 0.84 (0.73–0.92)
and 0.85 (0.76–0.94), in low and high nonrenal Sequential Organ
Failure Assessment score subgroups. Performance of the tissue
inhibitor of metalloproteinase-2 and insulin-like growth factorbinding protein 7 test was not modified by nonrenal Sequential
Organ Failure Assessment (p = 0.70). In multivariate analysis, the
addition of tissue inhibitor of metalloproteinase-2 and insulin-like
growth factor-binding protein 7 significantly improved the performance of a clinical model for predicting acute kidney injury
(p = 0.015).
Conclusion: Urinary tissue inhibitor of metalloproteinase-2 and
insulin-like growth factor-binding protein 7 accurately predicts
acute kidney injury in septic patients with or without other organ
failures. (Crit Care Med ; 44:1851–1860)
Key Words: acute kidney injury; insulin-like growth factor-binding
protein 7; organ dysfunction; risk prediction; sepsis; tissue
inhibitor of metalloproteinase-2

A

cute kidney injury (AKI) is one of the most common complications of sepsis and is associated with an
increased ICU and hospital mortality (1–7). The benefit of preventive and therapeutic measures for AKI has been
difficult to confirm because treatments are often initiated when
renal injury is already established (8, 9). Perhaps as a result, the
prognosis for sepsis patients with AKI remains poor.
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Biomarkers for AKI might allow for earlier initiation
or more tailored application of renal protection measures
and avoidance of iatrogenic harm (10, 11). Two novel urinary biomarkers, tissue inhibitor of metalloproteinases-2
(TIMP-2), and insulin-like growth factor-binding protein 7
(IGFBP7) have been validated for predicting moderate and
severe AKI (classified as AKI stage 2 and 3 according to the
Kidney Disease Improving Global Outcome [KDIGO] 2012
classification) (12) in critically ill patients. Both TIMP-2 and
IGFBP7 are markers of cellular stress in the early phase of
tubular cell injury caused by a wide variety of insults (inflammation, ischemia, oxidative stress, drugs, and toxins) (13–16).
Furthermore, both molecules can initiate G1 cell-cycle arrest
that prevents cells from dividing when potentially injured
(17). Importantly, both biomarkers also act as “alarm” proteins exerting paracrine effects on adjacent cells (18). The
product of these two biomarkers ([TIMP-2]·[IGFBP7]) outperformed all other known biomarkers or biomarker combinations for predicting moderate-severe AKI (19), and the test
has been validated using a clinical adjudication committee
as a gold-standard for AKI (20). Finally, [TIMP-2]·[IGFBP7]
measurement proved to be a highly sensitive predictor of AKI
in cardiac surgery patients (21).
Importantly, performance of novel biomarkers for AKI can
suffer in patients with sepsis presumably because many of the
pathologic processes of sepsis can affect biomarkers even without injuring the kidney (22). Furthermore, because the mechanisms of organ injury in sepsis may not be specific for the
kidney, nonrenal organ failures could mimic AKI (23). Thus,
we sought to evaluate the performance of [TIMP-2]·[IGFBP7]
in patients with sepsis, with or without nonrenal organ failures. We assessed this biomarker combination in a subset of
patients with early sepsis from the Sapphire (19) and Topaz
(20) prospective clinical trials using cutoff values of greater
than 0.3, 1.0, and 2.0 (ng/mL)2/1,000 (24). At the time of biomarker measurement and adjusting for common sepsis risk
factors, we evaluated test performance in conjunction with
bedside clinical parameters.

PATIENTS AND METHODS
Study Design
We conducted a preplanned subgroup analysis of critically ill
patients enrolled in either of our two previously reported studies on the discovery/validation (Sapphire) (19) and subsequent
secondary validation (Topaz) (20) of [TIMP-2]·[IGFBP7]. We
defined sepsis based on international consensus criteria and the
clinical diagnosis assigned by the treating physicians at enrolling sites (25). All patients were considered to be at high risk
for AKI, characterized by respiratory or cardiovascular dysfunction as previously reported (Fig. 1) (19, 20). The design,
execution, and reporting of this study meet the Strengthening
the Reporting of Observational Studies in Epidemiology (26)
and the Standards for Reporting of Diagnostic Accuracy criteria (27). Data were collected by the investigators and analyzed by independent statisticians not directly affiliated with
October 2016 • Volume 44 • Number 10
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testing was performed as previously described (19, 20).
We assessed severity of
illness and organ dysfunction/failure with the Acute
Physiology and Chronic Health
Evaluation (APACHE) III (28)
and Sequential Organ Failure
Assessment (SOFA) (29)
scores. Nonrenal APACHE III
and SOFA scores were calculated by subtracting the renal
components from these scores.
Statistical Methods
To assess the performance of
[TIMP-2]·[IGFBP7] in predicting AKI, we calculated area
under the receiver operating
characteristic curve (AUC),
sensitivity, specificity, negative
and positive predictive values
(NPV and PPV), and relative
risk (RR). The Delong method
was used to estimate the 95%
CI for AUC. Bootstrap method
was used to estimate the 95%
CI for sensitivity, specificity,
Figure 1. Study design. Acute kidney injury (AKI) defined as Kidney Disease Improving Global Outcome
NPV, and PPV, except for the
(KDIGO) AKI stage 2 or 3 (Sapphire) (19) and determined by clinical adjudication based on KDIGO stage 2–3
AKI (Topaz) (18).
cases where there were empty
cells and the Clopper-Pearson
Exact method was used instead.
the study. Both study protocols were approved by the Western RR was calculated at each [TIMP-2]·[IGFBP7] stratum relative
Institutional Review Board (Olympia, Washington, DC) and to the lowest stratum. The 95% CI for RR was calculated using
also by the institutional review board or ethics committee of
bootstrap method except when there were empty cells, and an
each study site if required. All patients (or authorized repreexact unconditional method was used instead (30).
sentatives) provided written informed consent. In this article,
To examine the effect of nonrenal organ dysfunction and
we present data from the Sapphire study, which defined AKI as AKI on the levels of [TIMP-2]·[IGFBP7], we performed a mulKDIGO stage 2–3 (12), and from the Topaz study, which used
tiple linear regression analysis where the response variable was
clinical adjudication for AKI (20), in order to examine the per- rank transformed [TIMP2]·[IGFBP7]; the explanatory variformance of the [TIMP-2]·[IGFBP7] test for risk assessment of
ables were AKI status, subgroup status according to the median
AKI in patients with sepsis.
of nonrenal SOFA scores, and the interaction between them.
The same analysis was also performed for each individual nonMeasurements
renal SOFA component.
Urine and serum samples for biomarker and creatinine assessTo assess the added value of [TIMP-2]·[IGFBP7] in predictment, respectively, were obtained within 24 hours of ICU ing AKI over using clinical variables alone, we constructed two
admission. TIMP-2 and IGFBP7 concentrations were measured multivariable logistic regression models: one with only clinical
by immunoassay with the NephroCheck Test on the Asute140 variables as explanatory variables and the other with the addiMeter (Astute Medical, San Diego, CA) by technicians blinded tion of [TIMP-2]·[IGFBP7] as an explanatory variable besides
to clinical data. Measurements of TIMP-2 and IGFBP7 were
clinical variables. A backward stepwise regression procedure
made at Astute Medical for the Sapphire study and in triplicate
with Bayesian Information Criteria was used to select which
at three independent laboratories (University of California at
clinical variables to be included the final models. Model goodSan Diego, CA; University of Louisville, KY; and ARUP Laboraness-of-fit was assessed using the Hosmer-Lemeshow method.
tories in Salt Lake City, UT) for the Topaz study. The median of
To quantify the added predictive ability of [TIMP-2]·[IGFBP7],
the triplicate values from Topaz was used for analysis, and val- we calculated integrated discrimination improvement (IDI)
ues were reported in units of (ng/mL)2/1,000. Serum creatinine
and category-free net reclassification improvement (cfNRI)
Critical Care Medicine
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using R package “PredictABEL” (31). In addition, we compared
the AUCs from these two models using the Delong method for
paired AUCs.
A p value of less than 0.05 was considered to indicate statistical significance. All reported p values are two sided. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC)
and R 3.1.0 (31).

RESULTS
Baseline and Clinical Characteristics
We included the 232 sepsis patients in the analysis, including 40 (17%) who developed AKI within 12 hours of testing. Baseline characteristics of all patients stratified by AKI
status are shown in Table 1. Almost half of the patients were

Table 1. Baseline Characteristics of Patients Grouped Acute Kidney Injury Versus No
Acute Kidney Injury
p

Variables

AKI

No-AKI

All patients

40

192

17 (43%)

102 (53%)

0.23

64 (16)

62 (17)

0.46

31 (26–39)

27 (24–32)

0.008

Male
Age (yr)

a

Body mass index (kg/m )

2 b

0.49

Race, n (%)
Black

5 (13)

Caucasian

17 (9)

29 (73)

154 (80)

6 (15)

21 (11)

4 (10)

11 (6)

0.30

Diabetes mellitus

13 (33)

52 (27)

0.56

Congestive heart failure

11 (28)

25 (13)

0.03

Coronary artery disease

8 (20)

42 (22)

0.99

24 (60)

111 (58)

0.86

5 (13)

32 (17)

0.64

16 (40)

61 (32)

0.36

6 (15)

8 (4)

0.02

1 (3)

22 (11)

0.14

Radiocontrast agents

13 (33)

67 (35)

0.86

Nephrotoxic drugs

39 (98)

171 (89)

0.14

Hematocrit < 30%

17 (43)

109 (57)

0.12

Nonrenal Acute Physiology and Chronic Health Evaluation III

73 (56–97)

61 (47–81)

0.008

9 (7–11)

7 (5–9)

0.02

Other/unknown
Medical history, n (%)
Chronic kidney disease

Hypertension
Chronic obstructive pulmonary disease
Cancer
Liver disease
Acute exposures and susceptibilities, n (%)
Emergency surgery

Nonrenal Sequential Organ Failure Assessmentc
Admitted to ICU
Emergency department

0.55
21 (53)

86 (45)

Ward

7 (18)

47 (24)

Operating room

2 (5)

23 (12)

Other hospital

9 (23)

31 (16)

Other ICU

0 (0)

2 (1)

Unknown

1 (3)

3 (2)
(Continued )
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Table 1. (Continued ). Baseline Characteristics of Patients Grouped Acute Kidney Injury
Versus No Acute Kidney Injury
Variables

AKI

No-AKI

p

36.3 (35.6–38.5)

36.6 (36.0–38.5)

0.21

119 (100–137)

116 (103–130)

0.96

30 (25–36)

29 (15–36)

0.63

Baseline variables
Body temperature (°C)b
Heart rate (beats/min)

b

Respiration rate (breaths/min)

b

Mean arterial pressure (mmHg)
WBC count (109/L)

b

b

24-hr fluid input (mL)

b

24-hr fluid output (mL)

b

56.0 (49.2–62.7)

61.0 (54.0–68.0)

0.007

15.2 (8.6–24.1)

13.8 (7.7–19.9)

0.39

4245 (3124–7097)

4280 (2616–5757)

0.35

975 (413–2251)

2195 (1500–3030)

< 0.001

% Fluid overload (1st 24 hr) ,

3.8 (1.3–7.4)

Mechanical ventilation

29 (73%)

121 (63%)

0.28

Vasopressor use

34 (85%)

128 (67%)

0.02

Blood transfusion

16 (40%)

58 (30%)

0.26

bd

1.9 (0.2–5.1)

0.92

Primary source of infection, n (%)
Abdomen

0.009

6 (15)

22 (11)

14 (35)

72 (38)

Skin or soft tissue

4 (10)

19 (10)

Urinary tract

6 (15)

37 (19)

10 (25)

42 (22)

Time from ICU admission to biomarker sample collection (hr)b

12 (7–18)

15 (8–21)

Enrollment serum creatinine (mg/dL)b,e

1.4 (1.0–1.9)

0.9 (0.7–1.3)

< 0.001

Tissue inhibitor of metalloproteinase-2 and insulin-like growth
factor-binding protein 7 [(ng/mL)2/1,000]

2.1 (1.1–4.3)

0.4 (0.2–1.0)

< 0.001

Lung

Other/unspecified

0.15

Average (sd).
Median (interquartile range).
c
Sequential Organ Failure Assessment score on the day of enrollment.
d
[Fluid input – output (L)/body weight (kg)] × 100 on the day of enrollment.
e
Hospital value taken closest to the time of enrollment.
a

b

referred from the emergency department with relatively short
delay between hospital and ICU admission (median [intraquartile range] time from hospital to ICU admission was 2 hr
[0–8 hr]). Exposure to radiocontrast agents and nephrotoxic
drugs and the presence of risk factors such as diabetes mellitus, coronary artery disease, and hypertension were similar in
patients who did or did not develop AKI. However, history of
congestive heart failure and liver disease were more common
in those patients developing AKI. Patients with AKI also had
lower mean arterial pressure and were more often treated with
vasopressors. Baseline serum creatinine and severity of illness
as judged by baseline nonrenal APACHE III and SOFA scores
were also greater for patients developing AKI (Table 1).
Biomarker Performance
The unadjusted RR for AKI by strata of [TIMP-2]·[IGFBP7]
defined by three cutoffs (0.3, 1.0, and 2.0) are shown in Figure 2.
Critical Care Medicine

The absolute risk in the low stratum (≤ 0.3) was 2.7% increasing
to 53.3% in the highest stratum (> 2.0) for an RR of 19.7 (95%
CI, 4.3–69.4; p < 0.001). Patients with AKI had significantly
higher levels of [TIMP-2]·[IGFBP7] than patients without AKI
(p < 0.001). This effect of AKI on [TIMP-2]·[IGFBP7] levels
was not modified by nonrenal SOFA (p = 0.70). In addition,
nonrenal SOFA subgroup did not affect [TIMP-2]·[IGFBP7]
values after adjusting for AKI status (p = 0.29).
The overall AUC for [TIMP-2]·[IGFBP7] for predicting AKI
in this cohort was 0.84 (0.77–0.90). For patients with a nonrenal SOFA score of greater than 7, the [TIMP-2]·[IGFBP7] AUC
was 0.85 (0.76–0.94) and similarly for patients with nonrenal
SOFA of less than or equal to 7, the AUC was 0.84 (0.73–0.92)
(Fig. 3). For comparison, the AUC for a serum creatinine
measured at the same time as urinary [TIMP-2]·[IGFBP7]
yielded AUC of 0.73 (0.59–0.85) for patients with a nonrenal
SOFA score of greater than 7 and AUC of 0.77 (0.65–0.87) for
www.ccmjournal.org
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B895) shows operating characteristics for [TIMP-2]·[IGFBP7]
cutoffs ranging from 0.1 to 5.0 at 0.1 intervals.

DISCUSSION

Figure 2. Unadjusted relative risk (with 95% CIs) for acute kidney
injury (AKI) stratified according to tissue inhibitor of metalloproteinase-2
and insulin-like growth factor-binding protein 7 [TIMP-2]·[IGFBP7]
concentrations in all patients. AKI risk in strata with [TIMP-2]·[IGFBP7]
values between 0.3 and 1.0, 1.0 and 2.0, and greater than 2.0 relative to
risk in the stratum less than or equal to 0.3. Relative risk estimates for the
upper two strata are significantly greater than 1 (*p < 0.01, **p < 0.001).
Total of 40 AKI subjects and 192 no AKI. Absolute risk in the less than
or equal to 0.3 stratum was 2.7% (95% CI, 0.33–9.4%). n = 74, 79, 34,
and 45 for strata less than 0.3, more than 0.3 to less than or equal to 1.0,
more than 1.0 to less than or equal to 2.0, and more than 2.0, respectively.

patients with a nonrenal SOFA score less than or equal to 7.
Similarly, estimated glomerular filtration rate yielded AUCs of
0.75 (0.61–0.87) and 0.76 (0.63–0.87).
Of note, we reported previously that for patients with sepsis
in the Sapphire study (19), the individual marker performance
for TIMP-2 was superior to IGFBP7, whereas the opposite
was true for surgical patients. Here, in this combined cohort
of sepsis patients, we again saw a better AUC for TIMP-2 0.84
(0.77–0.90) compared with that for IGFBP7 0.79 (0.72–0.86).
Interestingly, these results were unchanged across low and high
nonrenal SOFA subgroups.
[TIMP-2]·[IGFBP7] remained a strong predictor for AKI
after adjustment for clinical variables, including severity of illness (APACHE III), nonrenal organ dysfunction (SOFA), body
mass index, fluid output, and serum creatinine concentration.
Addition of [TIMP-2]·[IGFBP7] to a clinical model significantly improved its predictive ability from 0.86 to 0.94 (p =
0.015) (Table 2). We also performed cfNRI and IDI. Table S1
(Supplemental Digital Content 1, http://links.lww.com/CCM/
B893) shows that [TIMP-2]·[IGFBP7] improves the overall
predictive ability of the model (statistically significant AUC
increase, IDI, and cfNRI). ICU and hospital outcomes stratified by biomarker results are shown in Table S2 (Supplemental
Digital Content 2, http://links.lww.com/CCM/B894).
Finally, operating characteristics (sensitivity, specificity, PPV, and NPV) at all three cut-offs (0.3, 1.0, and 2.0) are
shown in Table 3. Sensitivity remains near 95% and specificity
near 90% for the 0.3 and 2.0 cut-offs, respectively. Table S3
(Supplemental Digital Content 3, http://links.lww.com/CCM/
1856
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For patients with sepsis, AKI is strongly associated with both
short- and long-term adverse consequences (1, 2). Indeed, in
a recent study of patients with septic shock, 60-day hospital
mortality was 6.2% for patients without AKI, 16.8% for stage
1, and 27.7% for stage 2–3 (32). Early and adequate treatment of sepsis might prevent sepsis-induced AKI, attenuate
AKI severity or might reduce the need for renal replacement
therapy (RRT) (33, 34). Rapid identification of septic patients
at high risk for developing AKI could substantially improve
the therapeutic approach. In this context, specific and sensitive
biomarkers of renal cell injury or stress could play an important role. We evaluated the performance of the novel urinary
cell-cycle arrest biomarker test [TIMP-2]·[IGFBP7] in septic
patients at high risk for developing AKI. We chose to assess risk
of moderate to severe AKI because this severity (corresponding
to KDIGO stage 2 and 3) has been shown to be associated with
a significantly increased prevalence of clinically important outcomes such as receipt of RRT and in hospital death (35), as well
as adverse effects on long-term survival specifically in patients
with sepsis (1).
Sepsis is a challenging area for AKI biomarkers. NGAL and
IL-18 have been examined as potential biomarkers of AKI, but
both are strongly influenced by systemic inflammation thus
degrading their specificity (36, 37). Although a small study
recently reported better performance of NGAL (both plasma
and urine) for AKI in patients with sepsis (AUCs, 0.83 and 0.89)
(38), most studies have noted modest performance of biomarkers in this population. Recently, a sophisticated machine-learning analysis was performed using candidate biomarkers selected
from extensive transcriptomic analysis to predict AKI on day 3
in pediatric patients with sepsis (37). Even after including AKI
status on day 1 in the model (positive in half the cases), the
AUC only reached 0.83 in the test cohort (37). These challenges
are perhaps not surprising because the mechanisms of organ
injury in sepsis may not be organ specific (37). However, our
results indicate that the performance of [TIMP-2]·[IGFBP7] in
patients with sepsis is not significantly confounded by nonrenal
SOFA. Thus, clinicians can rely on these biomarkers for predicting AKI even in the presence of nonrenal organ failures. This is
a notable advance in comparison with other biomarkers that
are available around the world (39–42).
As alluded to in a recent study of remote ischemic preconditioning (43), biomarkers of cell-cycle arrest such as TIMP-2 and
IGFBP7 may signal that the renal epithelium has been stressed
and has shut down function but may still be able to recover
without permanent injury to the organ. Importantly, both
TIMP-2 and IGFBP7 appear to be able to signal in autocrine
and paracrine fashions, thus spreading the “alarm” from the site
of injury (15, 44). In terms of timing, this signal could be ideal
as it may be early enough that management strategies can still
alter the outcome. This is particularly important in septic AKI
where delay and early timing remains a major issue (4, 32, 42).
October 2016 • Volume 44 • Number 10
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and hemodynamics can be
monitored more carefully.
Conversely, if the result were
less than 0.3, then the risk
would be less than 3% and
thus the patient could be safely
continued on current regimen.
Of course, biomarkers will
not take the place of clinical
judgment and the question
whether they offer information
in addition to clinical variables
is an important one. Although
clinicians are unlikely to use
statistical models at the bedside, the model shown in
Table 2 represents the limits
of information that can be
derived from clinical variables.
Indeed, the model used here
was developed in this dataset
Figure 3. Tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 [TIMPand is therefore likely over2]·[IGFBP7] and acute kidney injury (AKI) status within 12 hr for all patients and for subgroups according
trained. As such, it represents
to nonrenal Sequential Organ Failure Assessment (SOFA) score. Boxes and whiskers show, respectively,
interquartile ranges and total observed ranges, censored by 1.5 times the box range. Horizontal dashes within
and unrealistic “benchmark”
the boxes show the medians. SOFA scores were calculated from patient data collected on the day of enrollment.
to compare the biomarker.
Patients with AKI had significantly higher levels of [TIMP-2]·[IGFBP7] than patients without AKI (p < 0.001 by
Nevertheless, the markers show
Wilcoxon rank-sum test). In the linear regression model, where the response variable is rank transformed [TIMP2]·[IGFBP7] and the explanatory variables are AKI status, SOFA subgroup status, and the interaction between
added value even in this setthem, the interaction was not statistically significant (p = 0.70). [TIMP-2]·[IGFBP7] was greater in patients
ting. Recent work examining
with AKI than in those without AKI in both subgroups (p < 0.001), and there was no statistically significant
the role of electronic surveildependence of [TIMP-2]·[IGFBP7] on SOFA subgroup regardless of the AKI status (p = 0.29).
lance for AKI has shown that
although computer programs
Although not directly examined in these observational trican help identification of AKI, this alone may not improve
als, we hypothesize that early use of biomarkers of cell-cycle patient outcomes. Indeed, electronic alerts may be “too late”
arrest such as TIMP-2 and IGFBP7 could help clinicians interbecause they are based on creatinine that is too late. Wilson
vene early on and thus improve outcomes for patients at risk
et al (49) examined an electronic alert based on KDIGO stage
of or with early evidence of sepsis-induced AKI (45–47). Early
1 but could not demonstrate changes in physician practice or
awareness that a patient with sepsis is about to develop a major
patient outcome. Physicians may already be aware of an AKI
organ failure could change a number of clinical decisions. event and so do not change their management. Importantly,
For example, selection of antibiotics and dosing/monitorthe [TIMP-2]·[IGFBP-7] test was developed to assess risk for
ing of nephrotoxic medication (antibiotics or others) would
stage 2–3 AKI 12 hours prior to its clinical manifestation. This
be affected. The decision to give intravenous radiocontrast
has two important potential benefits over the electronic alert.
(especially intra-arterial) could be altered. Even the decision
First, 12 hours is a long time in the ICU and could be a decito discharge a patient or commence with a detailed diagnostic sive period to discontinue nephrotoxins, investigate the source
work-up would be influenced by the probability that a patient of sepsis, and improve resuscitation. Second, as many as 70%
has or will have AKI (48). For example, consider a patient with
of AKI alerts will be for patients that never progress beyond
sepsis admitted from the medical ward and started on broad stage 1 AKI. Alert fatigue is a large factor leading to clinicians
spectrum antibiotics including empiric coverage with vancoignoring alerts. The [TIMP-2]·[IGFBP-7] test was developed
mycin. The morning after admission (9 hr later), the blood
for stage 2–3 AKI, and thus it does not detect stage 1 conditions
pressure and heart rate were normalized and cultures were that are low risk for progression. Conversely, like all diagnospending. Now imagine that creatinine level of the patient was tics, biomarkers for AKI should not be used in patient popuslightly elevated (1.2 mg/dL from 1.0), but urine output was lations for which they were not developed. Low-risk patients
adequate. If the patient had a urinary [TIMP-2]·[IGFBP7]
(e.g., stable outpatients) will exhibit far greater false-positive
test result more than 2.0, the risk of developing stage 2–3 AKI rates compared with critically ill patients and would not be
would be more than 50% and the patient’s clinical team might
appropriate for the [TIMP-2]·[IGFBP-7] test.
well wish to stop or dose-adjust the vancomycin and perOur study has important strengths. We analyzed data from
haps keep the patient in the ICU where fluids, urine output, two large and unrelated cohorts with two different methods of
Critical Care Medicine
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Table 2. Multivariate Analysis of the Clinical Model With and Without Inclusion of Tissue
Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 for
Predicting Acute Kidney Injury in Sepsis
Clinical Model With
[TIMP-2]·[IGFBP7]

Clinical Model Alone
Odds Ratio (95% CI)

p

Odds Ratio (95% CI)

p

Acute Physiology and Chronic Health Evaluation III, nonrenal

1.02 (1.00–1.05)

0.04

1.03 (1.01–1.06)

0.01

Sequential Organ Failure Assessment, nonrenal

1.03 (0.84–1.27)

0.76

0.99 (0.79–1.24)

0.93

Body mass index

1.06 (1.02–1.10)

0.004

1.09 (1.03–1.14)

0.002

24-hr fluid outputa

0.03 (0.01–0.16)

< 0.001

0.07 (0.01–0.39)

0.002

Serum creatinineb

1.3 (1.1–1.5)

Variable

0.002

1.3 (1.1–1.6)

…

…

7.3 (3.1–17.5)

< 0.001

0.86 (0.78–0.94)

< 0.001

0.94 (0.90–0.98)

< 0.001

[TIMP-2]·[IGFBP7]a
Area under the receiver operating characteristic curvec

0.001

[TIMP-2]·[IGFBP7] = Tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7.
a
Log10 transform.
b
Log2 transform, serum sample collected simultaneously with urine sample for tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding
protein 7 ([TIMP-2]·[IGFBP7]) testing.
c
Area under the receiver operating characteristic curve was significantly (p = 0.015) greater with than without adding [TIMP-2]·[IGFBP7] to the model.

Operating Characteristics (95% CI) for Tissue Inhibitor of Metalloproteinase-2
and Insulin-Like Growth Factor-Binding Protein 7 Cutoffs 0.3, 1.0, and 2.0
Table 3.

Cutoff

%Subjects
Above Cutoff

Sensitivity

Specificity

Negative
Predictive Value

Positive
Predictive Value

All

0.3

68.1 (62.5–74.1)

95 (87.5–100)

37.5 (30.2–43.8)

97.3 (93.2–100)

24.1 (21.8–26.5)

All

1.0

34.1 (28.9–39.2)

77.5 (62.6–90)

75.0 (68.2–80.7)

94.1 (90.8–97.2)

39.2 (32.1–46.6)

All

2.0

19.4 (15.1–23.7)

60 (45–75)

89.1 (84.4–92.7)

91.4 (88.5–94.4)

53.3 (41.5–65)

Nonrenal SOFA ≤ 7

0.3

60.0 (51.7–69.1)

93.7 (81.3–100)

45.2 (34.6–54.8)

97.9 (93.5–100)

20.8 (17.2–24.6)

Nonrenal SOFA ≤ 7

1.0

28.3 (20.8–36.7)

68.8 (43.8–87.5)

77.9 (69.2–86.5)

94.2 (90.1–97.8)

32.4 (22.6–44.4)

Nonrenal SOFA ≤ 7

2.0

17.5 (11.7–24.2)

62.5 (37.5–87.5)

89.4 (82.7–95.2)

93.9 (90.2–97.8)

47.6 (30.4–66.7)

Nonrenal SOFA > 7

0.3

76.8 (68.8–83.9)

95.8 (87.5–100)

28.4 (19.3–37.5)

96.2 (88.0–100)

26.7 (23.9–30)

Nonrenal SOFA > 7

1.0

40.2 (32.1–48.2)

83.3 (66.7–95.8)

71.6 (62.5–80.7)

94.0 (88.5–98.5)

44.4 (35.7–55.6)

Nonrenal SOFA > 7

2.0

21.4 (15.2–27.7)

58.3 (37.5–75)

88.6 (81.8–94.3)

88.6 (83.7–93.3)

58.3 (42.9–76)

Subgroup

SOFA = Sequential Organ Failure Assessment.

determining the AKI endpoint (KDIGO stage 2–3 and clinical
adjudication). However, this could be viewed as limitation, and
there are also other important limitations to this work. First,
because the Sapphire and Topaz clinical trials were not specifically designed to examine sepsis-induced AKI, we did not
collect information on the type of organism or on the timing
of infection. Nonetheless, our results are consistent across both
multicenter cohort studies. Second, long-term outcomes were
not available or was quality of life assessed in the Topaz study.
Third, and most importantly, we could not examine whether
the availability of biomarker results would have changed
patient management or outcomes. This question awaits further
study. However, given the limited information in the literature
about the performance of biomarkers in sepsis-induced AKI,
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despite its common occurrence, we believe that our results
should inform clinical practice and future research.

CONCLUSIONS
The urinary [TIMP-2]·[IGFBP7] test provides accurate prediction of AKI in septic patients, and test performance is not
affected by nonrenal organ dysfunction. As such, the test may
extend the therapeutic window for renal protection and potentially enhance (future) therapeutic interventions to prevent or
attenuate AKI.
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